| This week's sponsor is Premier Research. | | | Rare Cancer Drug Research: What to Know Going In
Rare cancer drug research requires oncology and rare disease expertise and careful attention to trial design and regulatory demands. Get started with our white paper. Premier Research. It's what we do. Best. |
Today's Rundown U.K. creates £2.5B investment program to help startups grow Alta raises $130M for its new biotech VC fund, missing its $200M goal Apexigen, BMS to combine CD40 and anti-CSF-1 drugs with Opdivo in new study Argenx boosts pipeline with new version of lead drug What’s a move to New Jersey worth? For Teva’s U.S. headquarters, $40M in tax breaks Featured Story | | | Thursday, June 14, 2018 The U.K. has set up a £2.5 billion ($3.6 billion) patient capital program. The fund is part of an initiative to help British biotechs grow into standalone midsized businesses, rather than sell up at the first sign of a takeover bid from overseas. |
|
|
| This week's sponsor is Catalent. | | | |
Top Stories Wednesday, June 13, 2018 Healthcare venture capital firm Alta Partners has launched a new fund focused on companies developing new therapeutics and health technology services. It closed with $130 million, below the $200 million it had hoped to raise according to a February 2017 SEC filing. Thursday, June 14, 2018 Apexigen is collaborating with Yale Cancer Center on an early-stage clinical trial that combines the biotech’s APX005M CD40 activator with Bristol-Myers Squibb’s Opdivo and cabiralizumab, an investigational anti-CSF-1 antibody, in patients with advanced solid tumors. Thursday, June 14, 2018 Argenx has the first data on a new subcutaneous formulation of its rare autoimmune disease drug efgartigimod that could make it a much more patient-friendly prospect. Wednesday, June 13, 2018 Teva has long called Pennsylvania its U.S. home base, but New Jersey has pushed through tax breaks designed to woo it away. For $40 million in incentives, the generics giant would have to promise a 1,000-strong workforce—and for Teva, that means keeping some jobs slated for the ax. | This week's sponsor is cobra:bio. | | | Accelerating Protein Production Since 1995
Cobra’s maxXpress service uses UCOE technology enables rapid production of monoclonal antibodies (mAbs), recombinant proteins and biosimilars while ensuring efficient, stable expression. More... |
Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Presented by: CMK Select Your product launch is coming. Are you prepared to go face-to-face with the marketplace? Learn how to create a foundation for success, drawing upon our experience with more than 65 launches. Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented By: Covance A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today! Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Innovation, Collaboration and Entrepreneurship in Drug Discovery June 28, 2018 | Cambridge, UK CBI’s 14th Annual Medical Device Compliance Congress (MDCC) June 14-15, 2018 | Chicago, IL Sensors Expo & Conference Conference & Expo: June 26-28, 2018 | Pre-Conference Symposia: June 25, 2018 | San Jose, CA Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 